Home / Research / Galenics Platform
Home / Research / Galenics Platform
Galenics Platform

    The GALENICS PLATFORM of SPST offers opportunities for collaborative research toward innovative new drug discovery and development. The primary goal of the platform is to achieve greatest success through collaborative innovation, aimed at: tackling of new scientific challenges on biotarget discovery; molecular targeting and functional drug delivery; unveiling the molecular mechanism of key biotargets in drug discovery for life-threatening diseases.  

    The framework of our collaborative research covers Medicinaal chemistry, Molecular & structural biology, Cellular pharmacology, Pharmaceutics, Computational bioinformatics and Analytical chemistry.

    Specific research areas of the Galenics Platform include: 1) design and development of tumor, immune system and CNS (BBB) targeted diagnostic or therapeutic drugs; 2) discovery and development of novel drug-delivery carriers and technologies; 3) structural and mechanistic studies of functional drug-delivery carriers and transporters. 

123.png

  • Qingzhi Gao

    The research of the Gao group covers medicinal chemistry and molecular targeting, synthetic chemistry and organo catalysis, and computer-aided drug design, aimed at the discovery of functional drug delivery carriers and understanding mechanisms of molecular targeting. Specific areas include a) strategies for development of small molecular anti-cancer drugs for targeted therapy, b) design and development of actively transportable small molecule drugs or protein-drug conjugates, c) discovery and development of novel drug-delivery carriers and pharmaceutics based on supramolecular chemistry, d) computer aided molecular design and modeling for innovative drug discovery and mechanistic study of drug transporters.

  • Jianmin Bao

    The research of the Bao group involves 1) development of new analytical technologies, such as (a) wide bore electrophoresis (WBE), which increases sample loading significantly compared to capillary electrophoresis (CE) for better detection and easy interface with MS and other technologies;(b) WBE containing microchip systems; and (c) multi-dimensional separation systems; 2)development of innovative bio/analytical methods such as affinity CE and liquid phase microextraction (LPME) for proteomics and pharmaceutical analysis; 3) development of new separation media including various silica gel, polymeric resin, and even agarose gel based resins and their applications; and 4)new development of miniaturized and high throughput sample preparation techniques, such as fritless SPE, membraneSPE, supported liquid extraction (SLE) and fast protein precipitation, etc. 

     

  • Haixia Chen

    The research of the Chen group concerns isolation, identification, bioactivity, and mechanism of constituents from natural resources.  In particular, the group focuses on functional mechanism and structure-activity relationships of macromolecules (polysaccharides and proteins) as well as small biomolecules. Methods are being developed in the group to quantify bioactivity of polysaccharides and small biomolecules from Traditional Chinese Medicine and natural resources.  Additionally, the group investigates functional food and new medicine from natural sources.

  • Yunfei Du

    The research area of the Du group involves investigation of hypervalent iodine (III) – mediated transformations, including oxidative coupling, rearrangement, cascade reactions, and asymmetric reactions.  Additionally, the group develops metal-free methodology for the constructionof heterocyclic compounds and pharmaceutical agents.

  • Jianhui Huang

    The research of the Huang group encompasses three main areas:  1) Studies towards the synthesis of heterocycles via transition metal catalysis, 



    2) Design and synthesis of useful active pharmaceutical ingredients, and 



    3) Late-stage functionalization of drug molecules and other materials.





  • Nasir Jalal


    Primary Focus: Radiation Induced Bystander Mutagenesis (RIBE)

    Top: Construction of E-18 cell line (a modified WTK1 cell line) to measure bystander mutagenesis at a higher resolution. A unique 18 base sequence spliced into the TK1 gene of heterozygous host; which upon exogenous expression of the I-Sce1 restriction enzyme cuts at the 18 base sequence and renders a heterozygous cell line to homozygous recessive for the TK1 gene. Such recessive mutants can be screened using the mutation assay. Poisson distribution analysis allows the measurement of mutants in a 96 well assay to determine mutation frequency.  

    Bottom: Comet assay employed for semi-quantification of  I-Sce1 induced DNA damage in E-18 cells using fluorescence microscopy.


    Other research interests:

    Collaborating in the field of translational breast cancer research that is focused on identifying environmental risks, conceiving new therapeutic strategies, testing novel anti-cancer drugs and providing insight to develop new prototypes of biomedical equipment for in-vitro fertilization technology and tailored gene therapy. Also, interested in the screening of novel synthetic lead compounds (such as Akt 1, 2, 3) that have therapeutic potential against cancer target proteins.



  • Youxin Li

    Li’s research addresses development and application of electrophoresis techniques,heterogeneous catalysis and applications, chiral separation and applications, sample preparation and application, and high throughput drug screening based on hollow fiber member system development.

  • Hans Lischka

    The research in the group of Lischka involves investigation of defect structures in materials with current applications to: grapheme nanoribbons, excitonic coupling and charge transfer in p-conjugated polymers as applied to photovoltaics, photostability of DNA; development of high-level quantum hemical methods and computer codes in the framework of COLUMBUS; full parallelization of MRCI method including analytic energyg radients and nonadiabatic couplings; onthe-fly nonadiabatic photodynamics (programsystemNEWTON-X) with application to biological systems including QM/MM approach.

  • Rajavel Srinivasan

    The research in the group of Srinivasan encompasses two main areas, 1) Developing new reaction methodologies: The research topics under this area include bioorthogonal reactions, late-stage modification of advanced chemical entities, C-H activation, and high-throughput amenable synthesis – aiming at advancing the way organic molecules are made for drug discovery and chemical biology applications. 2) Inhibitor discovery based on fragment-based approaches: Design and synthesis of ‘unconventional’ fragments with rich structural diversity. These fragments will be used as a starting point towards novel inhibitors for unexplored biological targets such as the AurB-INCENP interaction.

  • Yanfang Su

    The research in the group of Su encompasses three main areas, including a) Isolation and identification of bioactive natural compounds from medicinal plants, b) Quality control of traditional chinese medicines, 3) Research & development of new medicines of natural origin

  • Fengping Tan

    The research in the group of Tan involves investigation into drug delivery systems.  This encompasses a) oral drug delivery systems, b) chronopharmaceutical drug delivery systems (ChrDDS), c) topical transdermal drug deliver and associated enhancements, and d) microencapsulation techniques.

  • Qianhong Wan

    The research in the group of Wan involves modern separation and analysis technology applied in pharmaceutical and biochemistry.  Specific areas include: 1) Synthesis and application of novel HPLC parking material, 2) Development of HPLC analysis methodology, 3) Chiral separation in HPLC and CE, 4) Magnetic separation technology and associated applications for purification of biological sample, and 5) Investigation of the motion character of magnetic beads under an external magnetic field.

  • Zheng Wang

    The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.

  • Donghua Wang

    The research in the group of Wang involves the design, synthesis, and biological activity evaluation of new compounds, with focus on industrialization of generic drugs, intermediates, and fine chemicals.  Specific areas include 1) Design and synthesis of the Rho kinase inhibitor, 2) Design and synthesis of the PDE4 inhibitor, and 3) Design and synthesis of antihistamine drugs

  • Jing Wei

    Wei’s research addresses mechanisms of drug activity with associated drug design.  Computational approaches (e.g., molecular docking, pharmacophore modeling, quantitative structure-activity relationship (QSAR), molecular dynamics) are used to identify and characterize putative ligand binding sites, elucidate binding mechanisms, and guide rational design of potentially new drugs.

  • Kenneth Woycechowsky

    The research in the Woycechowsky group focuses on the supramolecular chemistry of proteins. In particular, we are interested in proteins that assemble into symmetrical, closed-shell, polyhedral capsid structures. Protein capsids can act as molecular containers and delivery vehicles for a variety of molecular cargoes, and therefore are useful for bionanotechnological applications, such as drug delivery, catalysis, and materials synthesis. Protein engineering strategies are used to explore and exploit the supramolecular chemistry of protein capsids. This approach is inherently interdisciplinary, utilizing methods from biochemistry, biophysics, molecular biology, organic chemistry, and cell biology. Research projects in our lab fall into three main areas, including 1) capsid self-assembly, 2) molecular encapsulation, and 3) drug delivery.

  • Yong Zhang

    The research in the group of Zhang is encompassed in the areas of chiral separation and proteomics analysis.

  • Youcai Zhang

    The research in Zhang’s group focuses on the function of transporters and nuclear receptors in pharmacology and toxicology. The major projects include: 1) preclinical development of novel transporter/receptor-targeted drugs for metabolic diseases; 2) investigation of the role of intestinal microbiota in lipid metabolism; and 3) establishment of novel preclinical models to improve the prediction of drug-induced liver injury.

  • Kang Zhao

    The research in the group of Zhao is encompassed in 4 main areas, including 1) Medicinal Chemistry:  Design and synthesis of drug molecules, and development of synthetic route to drug intermediates, 2) Biological Organic Chemistry:  Investigation of anti-cocaine, monoclonal antibodies, and anti-viruses, 3) Organic Synthetic Methodology: Hypervalent iodine chemistry and heterocyclic chemistry, and 4) Total Synthesis of Complex Molecules: design and synthesis of natural products.

  • Yanjun Zhao

    The research in the group of Zhao encompasses four main areas, including (1) Stimuli-responsive drug delivery systems; (2) Ferroptosis-targeting nanomedicines; (3) Photo-triggered microtubule inhibitors; (4) Pharmaceutical micelles, biomaterials and nanomaterials.

  • Hongxia Zhao

    Zhao’s research addresses development of highly bioavailable drugs by targeting active drug transporters, with focus on issues of blood brain barrier-associated drug transport proteins and CADD-based molecular design of target selective drugs that can be substrates for such transporters and actively delivered into the central nervous system.  

  • Lijun Zhou

    The research in the group of Zhou encompasses three main areas, including, 1) Investigation of molecular pathogenesis of diseases and cell signaling pathways, and pharmacological mechanism of drug action, 2) Development of new small molecule based targeting anticancer drugs, e.g., TRAF6 as a new target of anti-tumor therapy, 3) Development of cells and C. elegans models, for high-throughput screenings, e.g., anti-aging drugs.

Galenics Platform

    The GALENICS PLATFORM of SPST offers opportunities for collaborative research toward innovative new drug discovery and development. The primary goal of the platform is to achieve greatest success through collaborative innovation, aimed at: tackling of new scientific challenges on biotarget discovery; molecular targeting and functional drug delivery; unveiling the molecular mechanism of key biotargets in drug discovery for life-threatening diseases.  

    The framework of our collaborative research covers Medicinaal chemistry, Molecular & structural biology, Cellular pharmacology, Pharmaceutics, Computational bioinformatics and Analytical chemistry.

    Specific research areas of the Galenics Platform include: 1) design and development of tumor, immune system and CNS (BBB) targeted diagnostic or therapeutic drugs; 2) discovery and development of novel drug-delivery carriers and technologies; 3) structural and mechanistic studies of functional drug-delivery carriers and transporters. 

123.png

  • Qingzhi Gao -- Leader

    The research of the Gao group covers medicinal chemistry and molecular targeting, synthetic chemistry and organo catalysis, and computer-aided drug design, aimed at the discovery of functional drug delivery carriers and understanding mechanisms of molecular targeting. Specific areas include a) strategies for development of small molecular anti-cancer drugs for targeted therapy, b) design and development of actively transportable small molecule drugs or protein-drug conjugates, c) discovery and development of novel drug-delivery carriers and pharmaceutics based on supramolecular chemistry, d) computer aided molecular design and modeling for innovative drug discovery and mechanistic study of drug transporters.

  • Jianmin Bao

    The research of the Bao group involves 1) development of new analytical technologies, such as (a) wide bore electrophoresis (WBE), which increases sample loading significantly compared to capillary electrophoresis (CE) for better detection and easy interface with MS and other technologies;(b) WBE containing microchip systems; and (c) multi-dimensional separation systems; 2)development of innovative bio/analytical methods such as affinity CE and liquid phase microextraction (LPME) for proteomics and pharmaceutical analysis; 3) development of new separation media including various silica gel, polymeric resin, and even agarose gel based resins and their applications; and 4)new development of miniaturized and high throughput sample preparation techniques, such as fritless SPE, membraneSPE, supported liquid extraction (SLE) and fast protein precipitation, etc. 

     

  • Haixia Chen

    The research of the Chen group concerns isolation, identification, bioactivity, and mechanism of constituents from natural resources.  In particular, the group focuses on functional mechanism and structure-activity relationships of macromolecules (polysaccharides and proteins) as well as small biomolecules. Methods are being developed in the group to quantify bioactivity of polysaccharides and small biomolecules from Traditional Chinese Medicine and natural resources.  Additionally, the group investigates functional food and new medicine from natural sources.

  • Yunfei Du

    The research area of the Du group involves investigation of hypervalent iodine (III) – mediated transformations, including oxidative coupling, rearrangement, cascade reactions, and asymmetric reactions.  Additionally, the group develops metal-free methodology for the constructionof heterocyclic compounds and pharmaceutical agents.

  • Jianhui Huang

    The research of the Huang group encompasses three main areas:  1) Studies towards the synthesis of heterocycles via transition metal catalysis, 



    2) Design and synthesis of useful active pharmaceutical ingredients, and 



    3) Late-stage functionalization of drug molecules and other materials.





  • Nasir Jalal


    Primary Focus: Radiation Induced Bystander Mutagenesis (RIBE)

    Top: Construction of E-18 cell line (a modified WTK1 cell line) to measure bystander mutagenesis at a higher resolution. A unique 18 base sequence spliced into the TK1 gene of heterozygous host; which upon exogenous expression of the I-Sce1 restriction enzyme cuts at the 18 base sequence and renders a heterozygous cell line to homozygous recessive for the TK1 gene. Such recessive mutants can be screened using the mutation assay. Poisson distribution analysis allows the measurement of mutants in a 96 well assay to determine mutation frequency.  

    Bottom: Comet assay employed for semi-quantification of  I-Sce1 induced DNA damage in E-18 cells using fluorescence microscopy.


    Other research interests:

    Collaborating in the field of translational breast cancer research that is focused on identifying environmental risks, conceiving new therapeutic strategies, testing novel anti-cancer drugs and providing insight to develop new prototypes of biomedical equipment for in-vitro fertilization technology and tailored gene therapy. Also, interested in the screening of novel synthetic lead compounds (such as Akt 1, 2, 3) that have therapeutic potential against cancer target proteins.



  • Youxin Li

    Li’s research addresses development and application of electrophoresis techniques,heterogeneous catalysis and applications, chiral separation and applications, sample preparation and application, and high throughput drug screening based on hollow fiber member system development.

  • Hans Lischka

    The research in the group of Lischka involves investigation of defect structures in materials with current applications to: grapheme nanoribbons, excitonic coupling and charge transfer in p-conjugated polymers as applied to photovoltaics, photostability of DNA; development of high-level quantum hemical methods and computer codes in the framework of COLUMBUS; full parallelization of MRCI method including analytic energyg radients and nonadiabatic couplings; onthe-fly nonadiabatic photodynamics (programsystemNEWTON-X) with application to biological systems including QM/MM approach.

  • Rajavel Srinivasan

    The research in the group of Srinivasan encompasses two main areas, 1) Developing new reaction methodologies: The research topics under this area include bioorthogonal reactions, late-stage modification of advanced chemical entities, C-H activation, and high-throughput amenable synthesis – aiming at advancing the way organic molecules are made for drug discovery and chemical biology applications. 2) Inhibitor discovery based on fragment-based approaches: Design and synthesis of ‘unconventional’ fragments with rich structural diversity. These fragments will be used as a starting point towards novel inhibitors for unexplored biological targets such as the AurB-INCENP interaction.

  • Yanfang Su

    The research in the group of Su encompasses three main areas, including a) Isolation and identification of bioactive natural compounds from medicinal plants, b) Quality control of traditional chinese medicines, 3) Research & development of new medicines of natural origin

  • Fengping Tan

    The research in the group of Tan involves investigation into drug delivery systems.  This encompasses a) oral drug delivery systems, b) chronopharmaceutical drug delivery systems (ChrDDS), c) topical transdermal drug deliver and associated enhancements, and d) microencapsulation techniques.

  • Qianhong Wan

    The research in the group of Wan involves modern separation and analysis technology applied in pharmaceutical and biochemistry.  Specific areas include: 1) Synthesis and application of novel HPLC parking material, 2) Development of HPLC analysis methodology, 3) Chiral separation in HPLC and CE, 4) Magnetic separation technology and associated applications for purification of biological sample, and 5) Investigation of the motion character of magnetic beads under an external magnetic field.

  • Zheng Wang

    The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.

  • Donghua Wang

    The research in the group of Wang involves the design, synthesis, and biological activity evaluation of new compounds, with focus on industrialization of generic drugs, intermediates, and fine chemicals.  Specific areas include 1) Design and synthesis of the Rho kinase inhibitor, 2) Design and synthesis of the PDE4 inhibitor, and 3) Design and synthesis of antihistamine drugs

  • Jing Wei

    Wei’s research addresses mechanisms of drug activity with associated drug design.  Computational approaches (e.g., molecular docking, pharmacophore modeling, quantitative structure-activity relationship (QSAR), molecular dynamics) are used to identify and characterize putative ligand binding sites, elucidate binding mechanisms, and guide rational design of potentially new drugs.

  • Kenneth Woycechowsky

    The research in the Woycechowsky group focuses on the supramolecular chemistry of proteins. In particular, we are interested in proteins that assemble into symmetrical, closed-shell, polyhedral capsid structures. Protein capsids can act as molecular containers and delivery vehicles for a variety of molecular cargoes, and therefore are useful for bionanotechnological applications, such as drug delivery, catalysis, and materials synthesis. Protein engineering strategies are used to explore and exploit the supramolecular chemistry of protein capsids. This approach is inherently interdisciplinary, utilizing methods from biochemistry, biophysics, molecular biology, organic chemistry, and cell biology. Research projects in our lab fall into three main areas, including 1) capsid self-assembly, 2) molecular encapsulation, and 3) drug delivery.

  • Yong Zhang

    The research in the group of Zhang is encompassed in the areas of chiral separation and proteomics analysis.

  • Youcai Zhang

    The research in Zhang’s group focuses on the function of transporters and nuclear receptors in pharmacology and toxicology. The major projects include: 1) preclinical development of novel transporter/receptor-targeted drugs for metabolic diseases; 2) investigation of the role of intestinal microbiota in lipid metabolism; and 3) establishment of novel preclinical models to improve the prediction of drug-induced liver injury.

  • Kang Zhao

    The research in the group of Zhao is encompassed in 4 main areas, including 1) Medicinal Chemistry:  Design and synthesis of drug molecules, and development of synthetic route to drug intermediates, 2) Biological Organic Chemistry:  Investigation of anti-cocaine, monoclonal antibodies, and anti-viruses, 3) Organic Synthetic Methodology: Hypervalent iodine chemistry and heterocyclic chemistry, and 4) Total Synthesis of Complex Molecules: design and synthesis of natural products.

  • Yanjun Zhao

    The research in the group of Zhao encompasses four main areas, including (1) Stimuli-responsive drug delivery systems; (2) Ferroptosis-targeting nanomedicines; (3) Photo-triggered microtubule inhibitors; (4) Pharmaceutical micelles, biomaterials and nanomaterials.

  • Hongxia Zhao

    Zhao’s research addresses development of highly bioavailable drugs by targeting active drug transporters, with focus on issues of blood brain barrier-associated drug transport proteins and CADD-based molecular design of target selective drugs that can be substrates for such transporters and actively delivered into the central nervous system.  

  • Lijun Zhou

    The research in the group of Zhou encompasses three main areas, including, 1) Investigation of molecular pathogenesis of diseases and cell signaling pathways, and pharmacological mechanism of drug action, 2) Development of new small molecule based targeting anticancer drugs, e.g., TRAF6 as a new target of anti-tumor therapy, 3) Development of cells and C. elegans models, for high-throughput screenings, e.g., anti-aging drugs.